Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Bin ^a   Luo, Xiao ^a   Deng, Binbin ^b   Giancola, JoLynn B ^a   McComb, David W ^b   Schmittgen, Thomas D ^c   Dong, Yizhou ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Ohio State University   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; LIPID; LUCIFERASE; MESSENGER RNA; NANOPARTICLE;

CHEMISTRY; GENETICS; HUMAN; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; LIPIDS; LUCIFERASES; NANOPARTICLES; RNA, MESSENGER;

EID: 84959314245     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22137     Document Type: Article

References (34)

1. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008).
2. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA 107, 1864-1869 (2010).
3. Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl. Acad. Sci. USA 111, 3955-3960 (2010).
4. Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo sirna delivery activity. Nat. commun. 5 (2014) doi: 10.1038/ncomms5277.
5. Li, B. et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano. Lett. 15, 8099-8107 (2015).
6. Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano. Lett. 15, 7300-7306 (2015).
7. Wang, M. et al. Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Adv. Funct. Mater. 19, 3112-3118 (2009).
8. Wang, M. et al. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Adv. Healthc. Mater. 3, 1398-1403 (2014).
9. Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005-1010 (2011).
10. Akinc, A. et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872-879 (2009).
11. Schroeder, A., Levins, C. G., Cortez, C., Langer, R. & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267, 9-21 (2010).
12. Altinoglu, S., Wang, M. & Xu, Q. Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications. Nanomedicine 10, 643-657 (2015).
13. Alabi, C. A. et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc. Natl. Acad. Sci. USA 110, 12881-12886 (2013).
14. Islam, M. A. et al. Biomaterials for mRNA delivery. Biomater. Sci. 3, 1519-1533 (2015).
15. Dong, Y. et al. Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo. Adv. Healthc. Mater. 3, 1392-1397 (2014).
16. Peng, H. et al. Polymeric multifunctional nanomaterials for theranostics. J. Mater. Chem. B 3, 6856-6870 (2015).
17. Cao, J. et al. A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomater. Sci. 3, 1545-1554 (2015).
18. Wang, Q. et al. Non-genetic engineering of cells for drug delivery and cell-based therapy. Adv. Drug Deliv. Rev. 91, 125-140 (2015).
19. Ikoba, U. et al. Nanocarriers in therapy of infectious and inflammatory diseases. Nanoscale 7, 4291-4305 (2015).
20. Peng, H., Wang, C., Xu, X., Yu, C. & Wang, Q. An intestinal trojan horse for gene delivery. Nanoscale 7, 4354-4360 (2015).
21. Du, D. et al. The role of glucose transporters in the distribution of p-aminophenyl-α -D-mannopyranoside modified liposomes within mice brain. J Control. Release 182, 99-110 (2015).
22. Liu, M. et al. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials 35, 3697-3707 (2014).
23. Li, M. H. et al. Tamoxifen embedded in lipid bilayer improved the oncotarget of liposomal daunorubicin in vivo. J. Mater. Chem. B 2, 1619-1625 (2014).
24. Xie, X. et al. Nanostraw-electroporation system for highly efficient intracellular delivery and transfection. ACS nano 7, 4351-4351 (2013).
25. Kariko, K., Muramatsu, H., Keller, J. M. & Weissman, D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20, 948-953 (2012).
26. Phua, K. K., Nair, S. K. & Leong, K. W. Messenger rna (mrna) nanoparticle tumour vaccination. Nanoscale 6, 7715-7729 (2014).
27. Sahin, U., Kariko, K. & Tu reci, O. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759-780 (2014).
28. Su, X., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In vitro and in vivo mRNA delivery using lipid-enveloped ph-responsive polymer nanoparticles. Mol. Pharm. 8, 774-787 (2011).
29. Tavernier, G. et al. mRNA as gene therapeutic: how to control protein expression. J. Control. Release 150, 238-247 (2011).
30. Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898-907 (2013).
31. 4 by a cyanuric acid based host via contact ion-pair interactions. Chem. Commun. 46, 6741-6743 (2010).
32. Mishra, S., Webster, P. & Davis, M. E. Pegylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83, 97-111 (2004).
33. Otsuka, H., Nagasaki, Y. & Kataoka, K. Pegylated nanoparticles for biological and pharmaceutical applications. Eur. J Cel. Biol. 64, 246-255 (2012).
34. Phua, K. K., Leong, K. W. & Nair, S. K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control. Release 166, 227-233 (2013).